Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bringing the Ovarian Cancer Test to Market

This article was originally published in Start Up

Executive Summary

An ovarian cancer assay based on protein pattern analysis is arousing excitement in a field all too often met with disappointment. Given initial excitement over the test and protein pattern analysis in general, business activity is likely to follow shortly. The NCI, FDA and a start-up, Correlogic Systems, are developing the test and taking it to large clinical trials this summer. Correlogic claims to have broad patents on pattern analysis for diagnostic purposes, a contention that is sure to lead to controversy, given the apparently high stakes.

You may also be interested in...



Molecular Dx as a Hot Spot

Although it's still a small portion of the $30-plus billion diagnostic services and test supplies business, molecular diagnostics is on disproportionately rapid growth curve. Some estimate its revenue growth at 25% a year compared to the overall industry average of 3-5%. Reimbursement is improving and robust new tests are emerging, slowly but steadily.

Molecular Dx as a Hot Spot

Although it's still a small portion of the $30-plus billion diagnostic services and test supplies business, molecular diagnostics is on disproportionately rapid growth curve. Some estimate its revenue growth at 25% a year compared to the overall industry average of 3-5%. Reimbursement is improving and robust new tests are emerging, slowly but steadily.

Predicant Biosciences Inc.

Among proteomics experts, however, a split has emerged between those who believe protein profiling patterns, rather than proteins themselves, are important indicators of disease, and those who believe that the proteins need to be identified before they can be useful clinically. Predicant Biosciences is taking the side of the former group, and, supported by a top-notch group of scientists and venture capitalists, is developing an integrated system it hopes will move the field forward.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel